paclitaxel has been researched along with Adenoma, Prostatic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhojani, N; Chughtai, B; Elterman, D; Gao, B; Lu, S; Zorn, KC | 1 |
| Espino, G; Estrella, R; Kaplan, SA; Lay, RR; Pichardo, M; Rijo, E | 1 |
| Douglas, DA; Gowardhan, B; Leung, HY; Mathers, ME; McCracken, SR; McKie, AB; Robson, CN | 1 |
| Nightingale, SL | 1 |
1 review(s) available for paclitaxel and Adenoma, Prostatic
| Article | Year |
|---|---|
New Technologies for Treatment of Benign Prostatic Hyperplasia.
Topics: Ablation Techniques; Alloys; Antineoplastic Agents, Phytogenic; Dilatation; Humans; Male; Minimally Invasive Surgical Procedures; Paclitaxel; Prostatic Hyperplasia; Prostheses and Implants; Robotic Surgical Procedures; Steam; Urinary Catheters | 2022 |
3 other study(ies) available for paclitaxel and Adenoma, Prostatic
| Article | Year |
|---|---|
One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia.
Topics: Aged; Coated Materials, Biocompatible; Drug Delivery Systems; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Paclitaxel; Prostatic Hyperplasia; Urinary Catheters | 2021 |
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Fibroblast Growth Factors; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Prostatic Hyperplasia; Prostatic Neoplasms; Recombinant Fusion Proteins; Tumor Cells, Cultured | 2005 |
From the Food and Drug Administration.
Topics: 5-alpha Reductase Inhibitors; Alkaloids; Androstenes; Antineoplastic Agents, Phytogenic; Azasteroids; Female; Finasteride; Humans; Male; Mammaplasty; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Prostatic Hyperplasia; Prostheses and Implants; Silicones; United States; United States Food and Drug Administration | 1992 |